Better Therapeutics Analyst Ratings
Better Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2022 | 842.76% | Chardan Capital | $17 → $14 | Maintains | Buy |
| 07/29/2022 | 1044.78% | Chardan Capital | $15 → $17 | Maintains | Buy |
| 03/16/2022 | 1112.12% | Chardan Capital | $17 → $18 | Maintains | Buy |
| 11/24/2021 | 1044.78% | Chardan Capital | → $17 | Initiates Coverage On | → Buy |
| 11/10/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/15/2022 | 842.76% | 查爾丹資本 | $17 → $14 | 維護 | 買 |
| 07/29/2022 | 1044.78% | 查爾丹資本 | $15 → $17 | 維護 | 買 |
| 03/16/2022 | 1112.12% | 查爾丹資本 | $17 → $18 | 維護 | 買 |
| 11/24/2021 | 1044.78% | 查爾丹資本 | → $17 | 開始承保 | →購買 |
| 11/10/2021 | — | 考恩公司 | 開始承保 | →跑贏大盤 |
What is the target price for Better Therapeutics (BTTX)?
Better Treeutics(BTTX)的目標價格是多少？
The latest price target for Better Therapeutics (NASDAQ: BTTX) was reported by Chardan Capital on November 15, 2022. The analyst firm set a price target for $14.00 expecting BTTX to rise to within 12 months (a possible 842.76% upside). 4 analyst firms have reported ratings in the last year.
查爾丹資本於2022年11月15日報道了Better Treateutics(納斯達克：BTTX)的最新目標價。這家分析公司將目標價定為14美元，預計BTTX將在12個月內上漲至(可能上漲842.76%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Better Therapeutics (BTTX)?
最新的分析師對Better Treeutics(BTTX)的評級是什麼？
The latest analyst rating for Better Therapeutics (NASDAQ: BTTX) was provided by Chardan Capital, and Better Therapeutics maintained their buy rating.
對Better Treateutics(納斯達克代碼：BTTX)的最新分析師評級由查爾丹資本提供，Better Treateutics維持買入評級。
When is the next analyst rating going to be posted or updated for Better Therapeutics (BTTX)?
下一次分析師評級將於何時發佈或更新，以改善治療(BTTX)？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Better Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Better Therapeutics was filed on November 15, 2022 so you should expect the next rating to be made available sometime around November 15, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查看公共財務報表，與Better Treeutics的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。上一次對Better Treeutics的評級是在2022年11月15日提交的，所以你應該預計下一次評級將在2023年11月15日左右提供。
Is the Analyst Rating Better Therapeutics (BTTX) correct?
分析師對Better Treeutics(BTTX)的評級正確嗎？
While ratings are subjective and will change, the latest Better Therapeutics (BTTX) rating was a maintained with a price target of $17.00 to $14.00. The current price Better Therapeutics (BTTX) is trading at is $1.49, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Better Treeutics(BTTX)評級保持不變，目標價在17.00美元至14.00美元之間。目前Better Treateutics(BTTX)的交易價格為1.49美元，超出了分析師的預測範圍。
譯文內容由第三人軟體翻譯。